Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15018272 | 0.83 | MEN1 (0.31) | — | |
| SCHEMBL28609060 | 0.83 | AR (0.31) | — | |
| SCHEMBL3693169 | 0.82 | CA2 (0.30) | CA2 | |
| SCHEMBL5928972 | 0.79 | TSHR (0.38) | — | |
| SCHEMBL677730 | 0.78 | CA2 (0.33) | CA2 | |
| SCHEMBL103466 | 0.77 | IDO1 (0.35) | — | |
| SCHEMBL900847 | 0.77 | — | — | |
| SCHEMBL2873786 | 0.76 | GABRA1 (0.37) | CA2 | |
| SCHEMBL29084727 | 0.76 | CA2 (0.32) | CA2 | |
| SCHEMBL6761318 | 0.73 | CA2 (0.30) | CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3753935-A1 | SUBSTITUTED DIALKYL(OXIDO)-LAMBDA4-SULFANYLIDENE NICOTINAMIDE DERIVATIVES AS KINASE INHIBITORS | ALLERGAN, INC. (US) | 2020-12-23 | — | — | EP | claimed |
| US-20200205406-A1 | MICROBIOCIDAL PHENYLAMIDINE DERIVATIVES WITH IMPROVED PLANT SAFETY PROPERTIES | SYNGENTA PARTICIPATIONS AG (CH) | 2020-07-02 | — | — | US | claimed |
| CN-105814021-B | Substituted nicotinamide derivatives as kinase inhibitors | 阿勒根公司 | 2020-03-13 | — | — | CN | claimed |
| EP-3599852-A1 | MICROBIOCIDAL PHENYLAMIDINE DERIVATIVES WITH IMPROVED PLANT SAFETY PROPERTIES | Syngenta Participations AG (CH) | 2020-02-05 | — | — | EP | claimed |
| WO-2018178057-A1 | MICROBIOCIDAL PHENYLAMIDINE DERIVATIVES WITH IMPROVED PLANT SAFETY PROPERTIES | SYNGENTA PARTICIPATIONS AG (CH) | 2018-10-04 | — | — | WO | claimed |
| EP-3080084-B1 | SUBSTITUTED NICOTINAMIDE DERIVATIVES AS KINASE INHIBITORS | ALLERGAN INC (US) | 2018-06-13 | — | — | EP | claimed |
| EP-3080084-A1 | SUBSTITUTED NICOTINAMIDE DERIVATIVES AS KINASE INHIBITORS | ALLERGAN, INC. (US) | 2016-10-19 | — | — | EP | claimed |
| EP-3080105-A1 | SUBSTITUTED DIALKYL(OXIDO)-LAMBDA4-SULFANYLIDENE NICOTINAMIDE DERIVATIVES AS KINASE INHIBITORS | ALLERGAN, INC. (US) | 2016-10-19 | — | — | EP | claimed |
| CN-105814021-A | Substituted nicotinamide derivatives as kinase inhibitors | 阿勒根公司 | 2016-07-27 | — | — | CN | claimed |
| US-20160194311-A1 | SUBSTITUTED NICOTINAMIDE DERIVATIVES AS KINASE INHIBITORS | ALLERGAN, INC. | 2016-07-07 | — | — | US | claimed |
| US-20060128715-A1 | Oxime derivative hydroxyethylamine aspartyl-protease inhibitors | ELAN PHARMACEUTICALS, INC. | 2006-06-15 | — | — | US | claimed |
| WO-2006010094-A1 | OXIME DERIVATIVE HYDROXYETHYLAMINE ASPARTYL-PROTEASE INHIBITORS | ELAN PHARMACEUTICALS, INC. (US) | 2006-01-26 | — | — | WO | claimed |
| WO-2006010095-A2 | OXIME DERIVATIVE SUBSTITUTED HYDROXYETHYLAMINE ASPARTYL PROTEASE INHIBITORS | ELAN PHARMACEUTICALS INC. (US) | 2006-01-26 | — | — | WO | claimed |
| US-20060014790-A1 | Methods of treatment of amyloidosis using spirocyclohexane aspartyl-protease inhibitors | ELAN PHARMACEUTICALS, INC. | 2006-01-19 | — | — | US | claimed |
| US-20050239790-A1 | Substituted hydroxyethylamine aspartyl protease inhibitors | ELAN PHARMACEUTICALS, INC. | 2005-10-27 | — | — | US | claimed |
| US-20050239836-A1 | Substituted hydroxyethylamine aspartyl protease inhibitors | ELAN PHARMACEUTICALS, INC. | 2005-10-27 | — | — | US | claimed |
| WO-2005087751-A2 | SUBSTITUTED HYDROXYETHYLAMINE ASPARTYL PROTEASE INHIBITORS | ELAN PHARMACEUTICALS, INC. (US) | 2005-09-22 | — | — | WO | claimed |
| WO-2005087752-A2 | SUBSTITUTED HYDROXYETHYLAMINE ASPARTYL PROTEASE INHIBITORS | ELAN PHARMACEUTICALS, INC. (US) | 2005-09-22 | — | — | WO | claimed |
| WO-2005070407-A1 | METHODS OF TREATMENT OF AMYLOIDOSIS USING ASPARTYL-PROTEASE INIHIBITORS | ELAN PHARMACEUTICALS, INC. (US) | 2005-08-04 | — | — | WO | claimed |
| EP-0194562-B1 | FUNGICIDAL COMPOSITION | TOSOH CORPORATION (JP) | 1990-10-03 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200205406-A1 | MICROBIOCIDAL PHENYLAMIDINE DERIVATIVES WITH IMPROVED PLANT SAFETY PROPERTIES | ARG1, MSR1, PADI1 | CA2 3178/4885 |
| US-20050239790-A1 | Substituted hydroxyethylamine aspartyl protease inhibitors | DNPEP, MME, ANPEP | CA2 3726/4885 |
| US-20060014790-A1 | Methods of treatment of amyloidosis using spirocyclohexane aspartyl-protease inhibitors | ASPH, DNPEP, ACE | CA2 1846/4885 |
| US-20160194311-A1 | SUBSTITUTED NICOTINAMIDE DERIVATIVES AS KINASE INHIBITORS | NADK, NME2, NME1 | CA2 2171/4885 |
| US-20060128715-A1 | Oxime derivative hydroxyethylamine aspartyl-protease inhibitors | ASPH, DNPEP, APP | CA2 1642/4885 |
| US-20050239836-A1 | Substituted hydroxyethylamine aspartyl protease inhibitors | DNPEP, MME, ANPEP | CA2 3726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.